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Abstract This review provides the background for
understanding the role of a battery of diagnostic
methods in paracoccidioidomycosis (PCM). This
systemic mycosis is a disease endemic in many
regions of Latin America, with sporadic cases also
occurring throughout the world (mycosis of importa-
tion). Although excellent laboratory methods for
diagnosis are available, there are deficiencies that
must be met by continued research. Understanding
the uses and limitations of a battery of laboratory
methods is essential to diagnose PCM. Clinicians and
laboratory directors must be familiar with the uses
and limitations of a battery of serologic and myco-
logical tests to accurately diagnose of PCM.
Antibody and antigen detections are valuable
adjuncts to histopathology and culture. More
recently, the gp43 and gp70 antigen detection assay
have improved the methodology of diagnosis of this
mycosis, which improves reproducibility and facili-
tates monitoring antigen clearance during antifungal
treatment. Furthermore, detection of antigen in cere-
brospinal fluid and in bronchoalveolar lavage fluid
increases the sensitivity for diagnosis of PCM in
central nervous system and in pulmonary infections,
respectively.
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Introduction
The fungus Paracoccidioides brasiliensis is
ensconced in the nature in Latin America, but its
exact niche is not known. The expanding human and
non-human populations of endemic areas provide a
continuing supply of individuals who are susceptible
to infection with P. brasiliensis. Paracoccidioidomy-
cosis (PCM) is caused by the inhalation of conidia
found in nature and under adverse nutritional condi-
tions, the fungus sporulates forming conidia which
are less than 5 lm in diameter and can easily reach
the alveoli when inhaled, and a lung-lymph node
primary complex develops. These early lesions may
remain silent for many years and in a manner similar
to tuberculosis and other systemic mycoses, they
may, at any time, progress in the lungs or disseminate
by lymphohematogenic route.
Serologic tests have served for several decades as
aid in the diagnosis and management of paracoccid-
ioidomycosis. Among the serologic tests available for
mycosis, those for paracoccidioidomycosis have been
the most reliable and have been useful in human
medicine.
The following serologic tests have been used for
diagnosing PCM: tube precipitin, complement
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fixation (CF), double immunodiffusion, counter-
immunoelectrophoresis (CIE), immunofluorescence,
radioimmunoassay, passive hemagglutination inhibi-
tion, immunoenzyme assays, such as ELISA,
MELISA, Dot Blot, Western Blot, and more recently
inhibition-ELISA.
Antigen preparation
In 1916, Moses [1] was the first to use P. brasiliensis
antigens for serologic testing, using a saline extract
from the fungus, for successful testing in CF. Since this
study, a number of different techniques for the use and
preparation of antigens have been described. However,
in 1955, Fava Netto [2] standardized a polysaccharide-
rich P. brasiliensis antigen to use in CF tests. With this
test and this kind of antigen, the serology for PCM
achieved a 90% sensitivity, thus demonstrating the
usefulness of the technique not only in diagnosis but
also in monitoring the course of the disease.
Double immunodiffusion (ID), that involves agar
or agarose gel support, is the most used test in
immunodiagnosis of PCM. The preparation of culture
filtrate antigens and their use for immunodiagnosis of
PCM by ID were pioneered by Restrepo [3] and
Negroni [4], who observed a level of sensitivity close
to 90%. During many years their antigens were
kindly supplied by them and used by almost all
laboratories working in this area.
For several years, many different antigenic prep-
arations have been used for the serodiagnosis of PCM
by ID. These various antigens lacked a standardized
preparation from one laboratory to another, and
included sonic extracts from the yeast forms, con-
centrated filtrates, and lyophilized to cite just a few
approaches. Moreover, each antigen was prepared
from cells grown in different culture media and under
different growth conditions (such as incubation time,
growth temperature, size of initial inoculum, and
shaken or stationary cultures). It is possible for
different antigenic preparations to vary considerably
in activity and quality as a result of lack of proper lot-
to-lot production standards even within the same
laboratory. With this variety of problems in produc-
ing a proper P. brasiliensis antigen, it is not
surprising that there is considerable disagreement
regarding the sensitivity of the ID test for the
serodiagnosis of PCM [5–11].
In 1988, we reported that a diagnostically
useful exocellular antigen preparation, Ag7, could
reproducibly be produced from yeast forms of
P. brasiliensis [12]. We suggested that this could be
used as a standard method in ID tests. The method
required, first, the determination of the number of
viable cells in a 3-day old pre-inoculum, the transfer
of this growth to Fernbach flask culture for 7 days,
the pooling of six lots consisting of three flasks each
in a total of 9.9 l medium, dialysis of this filtrate,
concentration by vacuum evaporation, new dialysis,
and finally lyophilization. The successful use of this
Ag7 is based on the presence of abundant amounts of
gp43, a 43,000-Da protein that is the immunodom-
inant antigen of the system and that is considered
specific for P. brasiliensis in ID tests. Since many
steps are necessary to obtain the final antigen
preparation, efforts were made to simplify the
methodology in order to circumvent the material
and economic difficulties found in most Latin Amer-
ican laboratories.
Since 1993, a simplified Ag7 antigen preparation
technique as described here has been reproduced
monthly in our laboratory with very good results. The
fungus was initially grown on Sabouraud medium
(SAB) slant tubes for 3 days at 35C. At that time,
growth (consisting entirely of yeast cells) was
collected from at least 10 tubes, yielding an inoculum
of approximately 2 · 106 cells. These cells were
inoculated into 500-ml Erlenmeyer flasks containing
100 ml yeast extract-peptone-dextrose (YPD) broth
(Difco). This culture was incubated for 3 days at
35C on a rotatory incubator at 50 r.p.m. The growth
obtained was transferred to 1,800-ml Fernbach flasks
containing 500 ml YPD broth. The flasks were
further incubated as above for 7 days. Supernatant
fluids were collected following paper filtration,
concentrated under vacuum at 45C, and dialyzed
against distilled water. The presence of gp43 was
monitored by sodium dodecyl sulfate/polyacrylamide
gel electrophoresis (SDS-PAGE) followed by silver
staining. After this step, the antigen was tested by ID.
If positive reactions were obtained with the control
sera, the antigen was aliquoted and maintained at
5C. If the reactions were negative, the antigen was
concentrated again and retested. In general, concen-
tration of the filtrate 10- to 15-fold is necessary.
This simplified protocol for Ag7 production has
shown a high degree of sensitivity, specificity, and
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reproducibility in the serodiagnosis of PCM. We
believe this procedure can be performed by most
laboratories, even those with relatively few
resources. Figure 1 shows the antigenic profile of
Ag7.
Antibody detection
During the process of infection, the antigens from
P. brasiliensis can activate B lymphocytes which
main function is to produce immunoglobulins (Ig).
These proteins play a crucial role in defense against a
variety of infectious microorganisms; they are present
in high concentrations in body fluids and in stable
form. These properties led to their relative ease of
detection and quantitation, providing major criteria
for the presence and activity of the disease (serodi-
agnosis), and for monitoring both evolution of the
disease and response to treatment.
In the management of a suspected PCM infection,
no diagnostic test is superior to the isolation of the
causative agent from a relevant clinical specimen, or
to its unequivocal physical identification in clinical
specimens and/or in histopathological setting of
tissue invasion. However, these ideal situations are
not always possible, and so one must often employ
diagnostic approaches that are based on serologic
testing. In the case of PCM, serologic testing, such as
immunodiffusion, is so reliable that a positive test,
even if the titer is low, is indicative of infection.
The last decades show a rapidly expanding field of
immunology permitting the development of several
new techniques, which were gradually being adopted
by researchers interested in the diagnosis of fungal
diseases, and several methods were currently being
used as possible aids in diagnosing some mycotic
infections, mainly PCM. Much of those serologic
assays utilize polyclonal/monoclonal antibodies or
antigens which can be easily quantified with high
sensitivity and have resulted in methods with more
sensitivity and specificity.
The successful application of serological tests for
diagnosing mycotic infections is very important
because the incidence and mortality of the mycoses,
particularly those caused by opportunistic fungi have
shown a marked increase in recent years, especially
in patients whose immune defense mechanisms have
been compromised by severe underlying diseases
such as AIDS, cancer, and hematologic disorders.
This emphasizes the utility of standardized tech-
niques and antigens as diagnostic tools in the clinical
and laboratory evaluation of patients with suspected
fungal infections. Fungal antigens are of great interest
not only for the study of their fundamental properties,
but also because of their use as reagents for the
diagnosis of fungal diseases.
The scientific literature on the immunology of the
mycoses for the last years shows an increasing
number of papers dealing with serological testing
and different antigenic preparations. In the early
1980s, Restrepo [13] reviewed the extensive litera-
ture about the serodiagnosis of PCM, and in the early
1990s, Mendes-Giannini et al. [14] wrote an excel-
lent chapter about the same subject. However, in the
early 1970s, Fava Netto [15] and Negroni [16] had
also documented the problems about antigens for
PCM diagnosis.
As there is extensive and diverse literature about
serology in PCM, in this article we will mainly
discuss our laboratorial experience, and the most
important advances in the PCM serology, in order to
show the current knowledge about the immunodiag-
nosis of PCM.
Fig. 1 SDS-PAGE
showing the antigenic
profile of a P. brasiliensis
exoantigen used in
immunodiffusion test. Gp43
is the predominant antigen
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Immunodiffusion
During the last years, immunodiffusion has been the
test of choice for the initial diagnosis of suspected
patients of PCM. The ID test has high specificity and
sensitivity may vary from 65 to 100% depending on
the kind of antigen used [14, 17]. Recently, the Ag7
was tested in ID by a multinational group of
researchers, with the aim of providing regional
laboratories, within the endemic areas, with an
accurate yet simple test to promptly diagnose PCM
[18]. The results showed that ID test was 84.3%
sensitive and 98.9% specific, concluding that in those
conditions the Ag7 can be regarded as an important
diagnostic tool in PCM. However, in our laboratory
false negative results have been occur in the order of
2–3%; these observations have also been noticed by
others [19]. In these cases, the PCM patients have
severe disease mainly with important pulmonary
involvement. On the other hand, the diagnosis may be
given by the finding of budding yeast cells in the
sputum by direct examination with 30% KOH. It is
our opinion that in these situations and in the moment
of diagnosis, the immune system of the patient is
depressed, and there is no sufficient antibodies to
precipitate in ID test. The paracoccidioidin skin test is
also negative. So the patient receives the initial
treatment and after a period of 1–2 months, immunity
is restored and ID test becomes positive (personal
observations). Itano [20] has proposed that this
problem may be due the presence of IgG asymmetric
antibodies which possess a structure resulting from a
predominant mannose-rich oligosaccharide moiety
linked to the Fd part of only one of the Fab arms of
the antibody molecule. As a consequence they are
functionally univalent, non precipitating. On the
other hand, Neves et al. [21] showed that the lack
of reactivity of sera from PCM patients in ID tests
may be related to the production of low-avidity IgG2
antibodies directed against carbohydrate epitopes.
Figure 2 shows a typical ID test for diagnosis of
PCM.
Counter-immunoelectrophoresis (CIE)
Counter-immunoelectrophoresis is another test used
to provide early diagnosis of PCM. Like in ID test,
the antigens used varied from laboratory to
laboratory, and they are extracts from sonicated yeast
cell suspensions, exocellular antigens from yeast or
mycelial cultures, cell-free antigens obtained from
yeast cells, and cross-reactions are due to the use of
unfractionated antigens. Counter-immunoelectropho-
resis is regarded as having a sensitivity equal to or
slightly greater than that provided by ID [22]. Some
authors related sensitivity between 77% and 97% and
specificity at least 95%. Some laboratories suggest
CIE as the first routine screening of sera from
suspected PCM patients, because the speed in which
results can be obtained. In our experience, the time
results in CIE is practically the same as in ID test.
After electrophoresis, the glass slide need to be
washed for 24 h, dried for further 24 h, and stained.
This is the same time necessary for ID test. On the
other hand, in CIE, it is necessary to use buffered
agarose, buffer and a power supply. These conditions
are not always accessible for laboratories in endemic
regions of PCM, in underdeveloped countries.
ELISA
Solid-phase immunoassays, especially enzyme im-
munoassays (ELISA), are popular for the quantitation
of antibodies both in research and clinical medicine.
Enzyme immunoassays employ antibodies or anti-
gens conjugated to enzymes in such a way that the
immunological and enzymatic moiety are preserved.
These assays give reliable and reproducible results
and are extremely sensitive. The basic principle of the
Fig. 2 Immunodiffusion test for paracoccidioidomycosis. In
the well center, Ag7 antigen; in the outer wells serum of PCM
patients
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method is the use of detector antibody reagents bound
to an enzyme indicator. The detector antibody is
chosen to react specifically with an antigen or
antibody component of interest. The amount of
detector bound to an antigen or antibody can then
be estimated by quantifying the enzyme activity that
remains associated with the system after the unbound
reagent is washed off. Since a single enzyme
molecule can catalyze the conversion of millions of
substrate molecules, the ‘‘signal’’ of bound detector
molecules is therefore greatly amplified, giving the
ELISA system a very high sensitivity. ELISA is
relatively simple to perform, gives quantitative
results, is highly sensitive and the reagents are
long-lived, can be safely shipped and conveniently
stored. Furthermore, different classes of immuno-
globulins can be determined thus allowing a more
precise evaluation of the humoral immune response.
Pons et al. [23] were the first to introduce ELISA
for detection of anti-P. brasiliensis antibodies.
ELISA has since been the basis of many other
publications for detection of serum antibodies to
P. brasiliensis [24–27], and has been used with a
range of different antigens, since crude mixtures,
partially purified and purified molecule as gp43, and
generally have high sensitivity, but not necessarily
been coupled with high specificity. Mendes-Giannini
et al. [24] and Camargo et al. [25] give a good
account to the development of the methodology of
ELISA for anti-P. brasiliensis antibodies. Mendes-
Giannini et al. [24] standardized ELISA using a
P. brasiliensis yeast filtrate as an antigen, and found
100% sensitivity and 88% specificity, considering a
cutoff of 1:40. However, cross-reactions were
observed with sera from patients with histoplasmosis
and Jorge Lobo’s disease. In order to overcome this
cross-reactivity, the authors standardized an ELISA-
abs test, in which the serum sample is first absorbed
with Histoplasma capsulatum yeast cells and also
with a mycelial filtrate. Camargo et al. [25] when
evaluating the serological response of PCM patients’
sera by ELISA, and using P. brasiliensis yeast filtrate
verified that the previous absorption of the sera with
dead cells of Candida albicans was necessary to
eliminate the cross-reactivity with heterologous sera.
The level of sensitivity and specificity achieved with
ELISA was 95% and 93.4%, respectively, consider-
ing a cutoff titer of 1:400. These filtrates are
constituted mainly by the glycoprotein gp43, the
immunodominant antigen. This molecule has also
been tested in ELISA, since when it was known as the
E2 fraction [14]. Mendes-Giannini [26] verified that
E2 (gp43) antigen did not cross-react, in ELISA, with
histoplasmosis, aspergillosis, Jorge Lobo’s disease,
sporotrichosis, tuberculosis, leishmaniasis sera when
previously adsorbed with a filtrate of H. capsulatum.
Puccia and Travassos [27] also tested gp43 in ELISA
and immunoprecipitation with 125I-labeled antigen,
and verified that most of the PCM sera recognized
primarily peptide epitopes of the gp43; however some
PCM sera were able to recognize carbohydrate
epitopes and accounted for up to 45% of the total
reactivity. 53% of the histoplasmosis sera reacted
within the same range of the PCM sera. Camargo
et al. [28], testing gp43 in antibody capture ELISA,
were able to discriminate among PCM and heterol-
ogous sera (histoplasmosis, Jorge Lobo’s disease,
candidiasis, aspergillosis). In this study, the minimal
titer obtained with PCM sera was 1:51,200 and the
maximal titer was 1:819,200; the arithmetical mean
titer was 1:549,093. Only one serum from Jorge
Lobo’s disease and one serum from aspergillosis had
maximal titer of 1:51,200. The sensitivity of the
capture ELISA was 100% and the specificity was
96.7%, considering the end point of reactivity.
However, if the analysis is made according to the
O.D., e.g., at the 1:800, 1:1,600, 1:3,200, etc., serum
dilutions, there occur enormous differences among
homologous and heterologous sera. At these dilu-
tions, the capture ELISA is 100% specific. In the
same study [28], gp43 was also analyzed by conven-
tional ELISA, with PCM and heterologous sera,
showing that heterologous sera reacted in the range of
PCM sera, mainly histoplasmosis and Jorge Lobo’s
disease sera. These contradictory results can be
explained by how gp43 is presented to be recognized
by antibodies in different tests. When gp43 is fixed
onto solid substrates, as in ELISA plates, made of
plastic, there are conformational changes in the
molecule, that cause the exposition of carbohydrate
epitopes recognized by heterologous sera; when the
molecule is in solution, as in capture ELISA (gp43 is
fixed on MAb anti-gp43), gp43 assumes different
conformation, presenting epitopes more reactive with
specific antibodies, those directed against protein
epitopes. Deglycosylation of gp43 frequently abol-
ishes the reaction of the heterologous sera with this
antigen [29]. The antibody capture ELISA represents
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an advance on the detection of specific antibodies,
once it uses specific monoclonal antibody against
gp43, which is fixed on the plates; however the users
depend on this MAb. Classical ELISA is really an
excellent format for the detection of antibody
response in PCM for many laboratories. As seen in
various reports, gp43 is not a totally specific mole-
cule, since its carbohydrate composition contains
epitopes recognized by heterologous sera, mainly by
histoplasmosis. However, one can perfectly separate
the heterologous sera, mainly histoplasmosis sera, by
the OD differences in each serum dilution. The gp43
may be considered a specific diagnostic antigen for
PCM, provided the presentation in classical ELISA
when the molecule is fixed directly on the plastic, or
in capture ELISA when it is fixed on the Mab anti-
gp43, and also how we interpret the results, consid-
ering the end point of reactivity or the OD in each
serum dilution.
Immunoblotting
Immunoblotting is a procedure in which antigens
separated by polyacrylamide gel electrophoresis are
transferred (blotted) to nitrocellulose sheets, allowed
to react with antisera, then sites where antibodies
have bound to antigens are revealed by means of
enzyme detector reagent and specific substrate. The
procedure has been used to identify P. brasiliensis
antigens that recognize antibodies in patient’s sera
[30–33].
Camargo et al. [30], using a P. brasiliensis yeast
exoantigen, standardized the Western blot for diag-
nosis and follow-up of PCM patients. Anti-P.
brasiliensis IgG reacted with four major components
of 70, 52, 43, and 20–21 kDa. The 43-kDa glyco-
protein was the predominant IgG reactive antigen,
recognized by 100% of the patient’s sera; the 70-kDa
antigen was recognized by 96% of the PCM sera.
Cross-reactivity could be minimized by serum dilu-
tion. In this study the authors considered gp43 and
gp70 as marker for human PCM. The authors studied
25 sera from patients prior antimycotic therapy and
72 sera of patients under therapy; the later patients
presented an decrease of antibody titers against gp43
and gp70. In other study, Blotta and Camargo [33]
studying 60 PCM patients’ sera (30 acute form and 30
chronic form) found that gp43 was recognized by
100% of sera (IgG), corroborating previous findings.
Mendes-Giannini et al. [32] studied the Western
blotting assay based the profile showed by sera from
patients with the distinct forms of PCM, both before
and after therapy. The majority of the sera recognized
gp43, but other molecules were also recognized.
Although Western blotting is highly sensitive and an
clear assay, it is not accessible for all laboratories in
the PCM endemic regions of Latin America. Figure 3
shows a typical PCM immunoblot reaction. However,
Taborda and Camargo [34], using an other format, a
dot immunoassay, could provide a more user-friendly
means of antigen detection (gp43) for PCM diagno-
sis. In this circumstance, they treated gp43 with
sodium metaperiodate to abolish cross-reactivity with
histoplasmosis sera, obtaining specific reactions.
Antigen detection
In the past some investigators have tried to detect
circulating antigen in PCM patients using polyvalent
antigens or antibodies in different assays such as
competition enzyme-linked immunosorbent assay
(ELISA) [35] immunoradiometric assay [36], CIE
[37], immunoelectrophoresis-immunodiffusion [38],
passive hemagglutination inhibition [39], inverted
linear immunoelectrophoresis [40], and immunoblot-
ting [41]; but all of these assays presented low
sensitivities. Go´mez et al. [42] were the first to use
monoclonal antibodies (Mabs) to detect the 87-kDa
circulating antigen in PCM patients by inhibition
ELISA (inh-ELISA), which showed 80.4% sensitiv-
ity. More recently, in our laboratory, the same
technique was used to detect gp43 and gp70 in
different specimens of PCM patients [43, 44].
Fig. 3 Representative
immunoblot of PCM
patient’s sera, showing the
main reactive molecules
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Detection of antigen in serum (gp43 and gp70)
One of the main problems in the serodiagnosis of
PCM based on antibody detection is the cross-
reaction obtained with sera from patients with other
mycoses, mainly histoplasmosis and lobomycosis.
Tests based on ID are generally considered to have
high specificity in the diagnosis of PCM, but lack in
sensitivity. Estimates of the sensitivity of immuno-
diffusion-based tests vary from 65% to 100% [17]
depending of the kind of antigen preparation used. On
the other hand, tests with higher sensitivity, such as
immunoenzymatic assays, present problems associ-
ated with specificity due to cross-reactivity with
heterologous sera, i.e., patients with non-PCM fungal
infections.
A more rational approach to the diagnosis of PCM
may be the detection of P. brasiliensis-gp43 antigen
in body fluids. The gp43 is a P. brasiliensis yeast-
phase extracellular antigen and its detection in
patients with proven PCM has been tested previously
by many approaches. However, these tests varied in
sensitivity and specificity, and in most of the studies
only a small number of patients were analyzed.
Mendes-Giannini et al. [41] detected the gp43
antigen in pools of PCM patients’ sera by Western
blot assay, but no quantitation was attempted. Freitas-
da-Silva and Roque-Barreira [35], using competitive
ELISA, detected circulating antigens in 33.7% of 88
PCM patients’ sera, whose antigen levels varied from
0.03 to 3.4 lg/ml. However, cross-reactions were
obtained with heterologous sera, such as sera from
patients with aspergillosis, cryptococcosis, and
histoplasmosis.
The most refined study of PCM antigenemia was
conducted by Go´mez et al. [42] using monoclonal
antibodies directed against an 87-kDa antigen of Pb
(gp87) in an inh-ELISA and detected the presence of
antigen in cases of PCM. In this study antigen
concentrations as low as 0.0058 lg/ml of serum
could be detected in sera from 46 PCM patients with
PCM, showing 80.4% sensitivity. Moreover, consid-
ering sera of patients with the acute form of the
disease, the inh-ELISA exhibited 100% sensitivity,
with the highest antigenemia (mean, 16.25 lg/ml),
while 83.6% of the patients with the multifocal
chronic form of PCM showed a mean antigenemia of
14.92 lg/ml and 60% of patients with the chronic
unifocal form showed a mean antigen concentration
of 14.7 lg/ml. Cross-reactions with aspergillosis and
histoplasmosis were also observed. Also, the authors
observed cross-reactions with sera from patients with
tuberculosis. They assumed that coinfection with
tuberculosis and PCM was a possible explanation for
these cross-reactions.
The inh-ELISA was tested in our laboratory and it
was able to detect gp43 antigen in the concentration
ranging from 0.0053 to 30 lg/ml of serum. The
overall sensitivity of the test among 81 PCM patients
was 95.1%, with a higher sensitivity in patients with
the acute form of PCM (100%) with a mean antigen
concentration of 18.23 lg/ml. Among the PCM
patients with the chronic form, gp43 was detected
in 95.71%, with mean concentration of 8.55 lg/ml.
Our results showed that the gp43 detection assay can
be used for both clinical forms of the disease.
Consequently, the gp43 antigen detection test may
be a valuable tool in PCM diagnosis. Gp43 detection
by this inh-ELISA showed 95.1% sensitivity which
was higher than the 80.4% sensitivity previously
reported by Go´mez et al. [42] to detect the 87-kDa
antigen, and also much higher than the 33.7%
sensitivity previously described by Freitas-da-Silva
and Roque-Barreira [35]. The use of the 43-kDa
antigen detection system provide a rapid, sensitive,
and specific mean to diagnose and differentiate
between acute and chronic disease. Moreover, this
test system’s true potential may lie in tracking the
course of antimycotic therapy by monitoring the
reduction in fungal load as evidenced by a sequential
reduction in antigen detected [43]. Figure 4 shows
the results of gp43 detection in PCM patient’s sera,
and in control groups.
Detection of low amounts of gp43 in some normal
serum controls may represents PCM subclinical
infection in normal people. PCM subclinical infection
is defined as an asymptomatic infection caused by
P. brasiliensis in normal individuals who live in an
endemic area and prove reactive to the paracoccid-
ioidin skin test [45]. Positive paracoccidioidin skin
testing in health population may vary from 3.70% to
62.60%, depending on the kind of antigenic prepa-
ration [46]. In our previous study, using gp43 or a
polysaccharide antigen (Fava Netto’s antigen) as
paracoccidioidin, 5% of healthy people reacted
positively to both antigens [47].
An other special antigen searched in biological
fluids of patients with PCM is the 70 kDa molecule.
Mycopathologia (2008) 165:289–302 295
123
In this sense, the overall sensitivity of gp70 detection
among 81 PCM patients was 98.8% in the presence of
a mean antigen concentration of 8.19 lg/ml and
reached 100% in patients with acute form of the
disease, with a mean antigen concentration of
11.86 lg/ml. Among patients with chronic form of
PCM, antigenemia due to gp70 was observed in
98.43% of serum samples from patients with the
multifocal form (mean antigen level, 7.87 lg/ml); on
the other hand, the sera of 100% of the patients with
the chronic unifocal form had gp70, with a mean
antigen concentration of 4.83 lg/ml. No cross-reac-
tions were observed with sera from patients with
other mycosis [44].
Detection of antigen in the cerebrospinal fluid
The involvement of the central nervous system (CNS)
in PCM, neuroparacoccidioidomycosis (neuroPCM),
is secondary to the hematogenous dissemination of
the fungus. NeuroPCM usually occurs as a manifes-
tation of widely disseminated disease but,
occasionally, CNS may be the sole location of the
infection. Whenever the CNS is involved, neuro-
radiological methods such as computerized tomogra-
phy (CT) and magnetic resonance imaging (MRI) are
needed for the identification of expansive lesions.
NeuroPCM is usually represented by multiple or
solitary parenchymal lesions that lead to sensory
or motor deficits, seizures, changes in mental status,
and intracranial hypertension [48, 49]. However, the
definitive diagnosis of NeuroPCM may only be
obtained after visualization of the fungus in biopsy
material, fungal isolation by culture or by serological
methods. Considering the morbidity associated
with the invasive neurological procedures, clinicians
are not prone to indicate aspiration or biopsy of
CNS lesions. Therefore, sensitive and specific immu-
nodiagnostic assays to determine the presence of
P. brasiliensis in cerebrospinal fluid (CSF) specimens
are indispensable.
Marques da Silva et al. [50] detected circulating
gp43 and gp70 in all CSF samples from patients with
NeuroPCM, with a mean antigen concentration of
19.3 and 6.8 lg/ml, respectively. Gp43 and gp70
were also detected in 10 (91%) serum samples out of
11 samples obtained among those 14 neuroPCM
patients, with a mean antigen concentration of 4.6
and 4.0 lg/ml, respectively. Moreover, the antigen
concentrations were found considerably higher in
CSF than in sera, suggesting their local production,
and the concentration of gp43 was always higher in
relation to gp70 (19.3 vs. 6.8; P \ 0.001). These
results suggest that monitoring specific antigens of
P. brasiliensis may be helpful to define the diagnosis
of NeuroPCM. On the other hand, antibody detection
in CFS was negative when tested by ID but was
positive against both antigens when tested by ELISA,
despite at low titers. This data, from the limited
number of patients studied, allow us to assume that
the detection of antigen by inh-ELISA or the
detection of specific antibody by conventional ELISA
may be equally sensitive to identify NeuroPCM.
Since antigen values for gp43 were always higher
than those found for gp70, assaying only for gp43
may prove sufficient for that purpose.
Detection of antigen in bronchoalveolar lavage
fluid
Also, the inh-ELISA was applied to detect gp43 and
gp70 antigens in bronchoalveolar lavage fluids (BAL)
[51]. In this purpose, PCM patients furnished BAL
samples and gp43 and gp70 were detected in
all samples with an average concentration of 9.38
and 4.37 lg/ml, respectively. BAL fluid samples
from individuals with diseases other than PCM
gave negative results. These results suggest that
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Fig. 4 Detection of circulating antigen (gp43) in sera from
patients with PCM or with other mycoses and in normal human
sera by inh-ELISA. Groups studied: 1, PCM; 2, cryptococcosis;
3, histoplasmosis; 4, normal human sera
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monitoring specific antigens of P. brasiliensis in
BAL samples may be helpful in determining a
diagnosis of pulmonary PCM, particularly when the
infection is in its initial stage. Since antigen values
for gp43 were always higher than those found for
gp70, assaying only for gp43 may prove sufficient for
that purpose. No antibodies were detected in BAL
fluids when tested by ID, whereas antibodies against
both antigens were detected by ELISA, although the
titers were low. These results point out that
P. brasiliensis antigen detection in BAL fluid is a
valuable tool for diagnosis of pulmonary PCM.
Nevertheless, the limited clinical and radiological
information available for the small number of
patients enrolled in that study proscribed the possi-
bility of establishing a correlation between antigen
levels and the severity of the disease.
Detection of antigen in urine
Nowadays, few reports about the detection of
P. brasiliensis in urine were related. The 43-kDa
P. brasiliensis antigen has already been detected in
the urine of patients with PCM, and this molecule
was demonstrated earlier in urine of a patient with
acute PCM [14]. Gome´z et al. [42], using an
inh-ELISA, reported the presence of an 87-kDa
P. brasiliensis antigen in urine samples with low
sensitivity in both reports. Salina et al. [52] used
immunoblotting and competition enzyme immunoas-
say techniques for the detection of circulating antigen
in urine samples. Both tests were specifics, and gp43
remained present in the urine samples collected
during the treatment period, with a significant
decrease in reactivity in samples collected during
clinical recovery and increased reactivity in samples
collected during relapses.
In our laboratory, Marques da Silva [53] employ-
ing the inh-ELISA, reported the detection of gp43
(mean = 8.65 lg/ml) and gp70 (mean = 8.96 lg/ml)
in the urine of PCM patients with 87.5% sensitivity
and 100% specificity to both molecules. No cross-
reaction was obtained when urine from patients with
other mycosis (histoplasmosis, candidiasis, and
cryptococcosis) besides normal human urine were
tested. In this study, urine samples were taken
before antifungal treatment. The inh-ELISA used in
our laboratory allowed the detection of antigen
concentrations in urine ranged 0.5–25 lg/ml. Despite
the high sensitivity, the presence of gp43 and gp70
antigens could not be detected in 12.5% of the urine
samples tested.
Antigenemia during therapy
There is no consensus about the optimal duration of
antifungal treatment for patients with PCM, but
several publications have advocated that detection
of circulating specific antibodies is an important
parameter to define the time to stop antifungal
treatment. However, PCM patients have a strong
specific antibody response against gp43 that may
persist throughout life. In contrast, some patients,
depending on their immune status, are serologically
negative at the time of diagnosis, with others showing
low levels of specific antibodies for long periods of
time. Consequently, sometimes it is very difficult to
determine whether these patients are ever cured [54].
One of the main challenges in PCM is to establish
when the clinician should stop the antimycotic
therapy because there is no consensus about treatment
options or about when the patient is really cured.
Although healing of apparent lesions may occur
within a short time after treatment is initiated, long
therapeutic courses are desirable in order to prevent
relapses. In this case, the host response must be
monitored by indirect methods and, in this scenario,
serology provides information about prognosis.
Due to these limitations of the antibody detection
tests, some researchers have evaluated the perfor-
mance of assays for the detection of circulating
P. brasiliensis gp43 antigen for the diagnosis of
PCM. Some tests have been used to detect gp43
circulating antigen with partial success in PCM
[24, 35, 37–42].
Related to the detection of antigen during treat-
ment, Mendes-Giannini et al. [41], by means of
Western blot assay, and testing a pool of PCM sera,
observed that gp43 started to disappear from the
circulation after 10 months of chemotherapy and was
undetectable after 2 years of treatment. No quantita-
tive measurements were made in individual sera.
More recently, the same group [52] determined the
presence of P. brasiliensis antigens in the urine of
patients by an indirect competition enzyme immuno-
assay (EIA-c) and an immunoblot test for monitoring
Mycopathologia (2008) 165:289–302 297
123
the response to therapy. By means of EIA-c, the
presence of P. brasiliensis antigens could be detected
in 75% of the urine samples tested.
Recently, we have studied the behavior of gp43
antigenemia during the treatment of PCM patients
with Itraconazole (ITZ) until the apparent cure at the
end of therapy (i.e., after 8–12 months) [55]. PCM is
a chronic fungal infection that chiefly involves the
reticulo-endothelial system (RES), as well as the
lungs. The definition of cure or good clinical response
is sometimes difficult to establish considering the low
sensitivity of cultures, the lung sequels, and the
limitations related to the evaluation of the infectious
status at the RES. As a consequence, there is a
consensus that nonculture methods are useful tool to
help the clinician to better evaluate the therapy
response. In this study, we evaluated the antigen
levels of 23 PCM patients that were successfully
treated with ITZ. The definition of a successful
response to the treatment was based on the resolution
of all signs and symptoms related to the infection, as
well as improvement in the radiological findings. It is
important to highlight that during the 12-month
period of clinical follow-up, no single patient had
any clinical or radiological evidence of relapse.
Although we were not able to evaluate the behavior
of the antigen titles during a relapse episode of the
fungal infection, clinical improvement of all patients
was followed by a decrease of the antigen levels to
\5 lg/ml. This finding strongly suggests that gp43
antigenemia may be a useful tool for monitoring the
therapeutic response to antifungal treatment.
In this study population, decreasing levels of
P. brasiliensis gp43 were detected in patients during
ITZ therapy. Of the 23 patients studied, 2 had
antigenemia of\5 lg/ml after 2 months of treatment,
15 patients had antigenemia of \5 lg/ml after
3 months, and 5 patients had antigenemia of \5 lg/
ml after 6 months of treatment. Only 4 patients
presented negative levels of antigenemia at month
8. It was noted that, once decreased, the levels of
gp43 in serum remained low until the end of therapy.
On the other hand, in most cases, the antibody titers
seemed to decrease a little later than this, i.e., after
about 6 months of therapy. Some cases deserve
particular attention. For example, one of the patients
showed a decreased serum antigenemia after
8 months of treatment, but his anti-gp43 antibody
titers remained high (1:16) and did not change
throughout the period of treatment. In contrast, an
other patient had undetectable antibodies (as deter-
mined by the ID test) from the time of diagnosis to
month 11 of treatment but showed a substantial
decrease in antigenemia levels during treatment. In
conclusion, our results indicate that the detection and
quantitation of the immunodominant 43-kDa
P. brasiliensis antigen in sera by inh-ELISA is a
sensitive method to be used for monitoring patients
with PCM under treatment. Figure 5 shows the media
of circulating antigen concentrations in sera from
patients with PCM at the time of diagnosis and
during treatment. Table 1 shows the characteristics of
23 PCM patients treated with ITZ during the period
of treatment.
With respect to the follow-up of PCM patients
based on gp70 antigenemia, Marques da Silva et al.
[44] assessed the gp70-antigen clearance during
antifungal treatment of PCM with ITZ, comparing
serum samples collected at baseline and after 8–
12 months of therapy. All 23 patients selected for the
study showed a good clinical response to therapy,
with no relapse of fungal disease documented over
the follow-up period. Overall, decreasing levels of
P. brasiliensis gp70 were detected in patients during
successful antifungal therapy. In contrast, the ID
titers of these patients varied over the follow-up
period (1:16–1:2). At the time of diagnosis all
patients showed detectable gp70 antigen and anti-P.
brasiliensis antibodies (except for one patient with
negative ID). A significant decrease of gp70 occurred
during the first month of therapy in 22 patients; at the
end of therapy, only 4 (17.39%) patients had
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Fig. 5 Media of circulating antigen concentrations in sera
from patients with PCM at the time of diagnosis and during
treatment. Error bars indicate the standard deviations
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detectable gp70 antigen (antigen levels were
\2.5 lg/ml) and positive titers by ID. By the end
of the follow-up period, antibody titers were negative
in three patients and one had undetectable antibodies
(ID test) from the time of diagnosis to the end of
treatment. However, the level of the antigen was also
negative until the end of follow-up. Once decreased,
the levels of gp70 in serum persisted low until the end
of therapy. On the other hand, in various cases,
antibody titers seemed to decrease a little later, after
about 6 months of therapy. After the period of
antifungal therapy (8–12 months) all PCM patients
showed clinical improvement. In conclusion, our
results indicate that the detection and quantification
of P. brasiliensis gp70-antigen in serum by inh-
ELISA is a sensitive method for the diagnosis of
PCM and may be used to evaluate the clearance of
fungal burden during treatment.
Follow-up of PCM patients based on antibody
detection
There is no consensus among the different groups
about the ‘‘gold standard’’ method (based on
antibody detection) for the follow-up of PCM
patients. Some authors attempted to demonstrate
that there was an effective relationship between the
clinical and serological characteristics during the
evolution of PCM [56, 57]. Campos et al. [56]
compared various serological tests, such as CF, ID,
CIE, and Magnetic-ELISA (MELISA) to find out
the most effective tool for monitoring patients
under antimycotic therapy. In their study, using
semestral serology data, they showed that the
clinical maintenance correlated with CIE and CF
positive results; clinical remission was better
determined when ID and MELISA furnished
Table 1 Characteristics of
23 PCM patients treated
with ITZ in relation to
antigen levels
a L, lung; M, mucosa; G,
ganglion; Lx, larynx; Of,
oropharynx; S, skin; CNS,
central nervous system
Patient no. and
local of lesionsa
Age
(year)
No. of samples
tested
Time of
follow-up (months)
Antigen level (lg/ml) at:
Diagnosis First
follow-up
End of
treatment
1 (L, M, G) 67 8 11 10.5 8.25 0
2 (L, S, G) 40 7 9 12.75 4.36 0
3 (L, M, G) 51 7 9 7.12 2.85 0
4 (L, Of, G) 56 9 12 30.0 30.0 2.31
5 (L, S, M, G) 31 7 11 14.25 4.77 0
6 (L, M, G) 44 7 9 11.25 2.49 0
7 (L, G, Lx) 44 6 8 14.25 3.75 3.57
8 (L, M, G) 42 7 9 13.5 28.5 2.57
9 (L, M, G) 49 7 11 7.12 4.27 0
10 (L, M) 44 7 9 14.25 12.0 0
11 (L, M, G) 52 7 10 14.25 3.07 3.21
12 (L, M, G) 50 6 9 3.57 3.57 0
13 (L, M) 49 6 9 10.5 6.38 0
14 (L, M) 37 5 9 9.75 5.25 0
15 (L, M) 56 6 8 6.38 6.01 0
16 (L, M, G, Lx) 49 6 9 28.5 4.90 4.53
17 (L, M) 66 8 10 2.49 3.75 0
18 (L, M) 51 7 10 5.64 1.56 0
19 (L, Lx) 40 7 10 14.25 5.64 0
20 (L, M) 37 8 10 16.5 6.0 0
21 (L, CNS) 37 6 12 14.25 9.75 0
22 (L, M) 42 8 12 3.39 2.49 0
23 (L, M, G) 54 7 12 9.75 2.13 0
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negative results; also, they recommended the use of
ID and MELISA for a more accurate correlation
with clinical evolution.
Our experience with the follow-up of patients
under treatment for PCM has shown that many
times the antibody titers obtained by the ID test do
not correlate with the clinical status of the patient.
For example, in some cases elevated antibody titers
(1:64) were observed until the end of treatment
when the patients were clinically cured. On the
other hand, although for most patients low antibody
titers are related to the absence of clinical symptoms
(1:2 or 1:4), in some cases low titers are present for
months and in concert with clinical symptoms. Such
discrepancy between the clinical status of the host
and specific antibody detection is probably related to
the fact that the cellular response and not the
humoral response is the main immunologic mech-
anism able to contain P. brasiliensis in the infected
organism. For these reasons, the use of serology as a
single criterion of cure in PCM is controversial. In
clinical practice, clinical, radiological, mycological
and serological aspects must be evaluated over a
long period of observation in order to assess the
result of treatment.
Recently, in our laboratory, Alves [58] compared
three methods (ID, ELISA, and capture-ELISA) in
order to verify which one was better for the follow-up
of PCM patients. In that study, serum samples were
tested during the pretreatment period and after 6, 12,
and 18 months of treatment. Immunodiffusion and
capture-ELISA showed a significant decrease in titer
after 6 months in good responder patients. ELISA
detected decreasing titers only after 12 months of
therapy. None of the methods were able to predict
relapse of the disease prior to clinical observation,
and increased titers could be observed only later, after
the onset of relapse. Even with these limitations, that
study indicated that the ID test seemed to be the best
option for the follow-up of PCM patients compared to
the other two tests.
For diagnostic purposes, tests based on ID are
generally considered to have high specificity; how-
ever, false negative results may also occur. On the
other hand, tests with higher sensitivity, such as
immunoenzymatic assays, present problems associ-
ated with specificity due to cross-reactivity with
heterologous sera.
Conclusions
Our knowledge on the serology of paracoccidioid-
omycosis is almost ideal for diagnosing and
monitoring the disease. Diagnostic approaches to
PCM is well described and tests are reasonably
accurate, and recognized deficiencies justify ongoing
research. The laboratories in Latin America need to
improve their conditions in order to offer a battery of
tests for diagnosing and monitoring PCM patients.
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